

Influence of Titanium Dioxide Nanoparticles on Oxidative Stress and Pulmonary Dysfunction

Monir Doudi¹ and Mahbubeh Setorki^{2,*}

¹Department of Microbiology, Falavarjan Branch, Islamic Azad University, Isfahan, IR Iran

²Department of Biology, Izeh Branch, Islamic Azad University, Izeh, IR Iran

*Corresponding author: Mahbubeh Setorki, Department of Biology, Izeh Branch, Islamic Azad University, Izeh, IR Iran. E-mail: doctor.setorgi@gmail.com

Received: March 31, 2014; Accepted: May 9, 2014

Background: Given the high application rate of titanium dioxide (TiO₂) nanoparticles in various industries and importance of the liver in body detoxification, the present study reviewed the toxic effects of such nanoparticles on changes of hepatic enzymes and liver and lung tissues.

Materials and Methods: In this experimental study, 32 Wistar rats were randomly divided into 4 groups: control (treated with 0.5 mL normal saline) and three experimental groups. Group 1, 2, and 3 received 0.5 mL of solution containing 10, 100, and 300 ppm TiO₂ for 7 successive days, respectively. The effects of nanoparticles on serum levels of glutamate oxaloacetate transaminase (SGOT) and glutamate pyruvate transaminase (SGPT) were evaluated at 2, 7, and 14 days. After 14 days, the tissue of liver and lung was collected and investigated.

Results: Mean SGOT levels, two days after the intervention, in groups 1 and 3 were significantly greater than the control group. Group 3 had a higher toxicity on hepatic enzymes. The histological results of liver in group 1 showed hepatocyte vasculature and hypertrophy approximate and elimination of hepatic lobules, in group 2 showed, decreased effect of hepatocyte acidophilic and elimination of hepatic lobules, and in group 3 showed, shrinkage of central veins and immediate hyperemia. The histological results in lung, also, showed destruction of alveolus (group 1) and vasculature hyperemia in all groups.

Conclusions: It can be concluded that nanometer spherical-shaped TiO₂ nanoparticles, even in small amounts for medical purposes, causes cell toxicity. Further research is needed in order to study its effects on organs and blood factors.

Keywords: Titanium dioxide nanoparticles; Toxic effects; Serum glutamic pyruvic; Transaminase; Serum glutamate oxaloacetate; Transaminase

1. Background

Industrial use of metal oxide nanoparticles (i.e. titanium oxide, iron oxide, silicon, and etc.) has rapidly grown during the past decade. This has led to increase in the occupational and environmental exposure of humans and other species to nanoparticles [1]. Many in-vivo studies suggested that nanoparticles can be accumulated in the liver, kidney, lung, spleen, brain, and heart, and can generate various inflammatory responses [2-8].

There has been extensive research by scientists and experts on the broad applications of titanium dioxide (TiO₂) nanoparticles in tumor therapy, drug and gene delivery to the cells and tissues, and labeling cells and macromolecules [9]. Therefore, few studies have been reported regarding their toxicity or side effects in vivo on cells and animals. Besides, the very limited numbers of studies that have been done in this field have had contradictory results.

For instance, Ge-yu et al. showed that transbronchial exposure to TiO₂ nanoparticles (with a size of 50 nm, and 0.5, 5.0, and 50.0 mg/kg nano-TiO₂) can induce oxidative stress in the liver and kidney but has no effect on the kidney and liver function that causes pathological changes [10].

In addition, Fabian et al. showed that TiO₂ nanoparticles

are well distributed through the liver, spleen, kidneys, and lungs, over time, without disruption of tissue. One month after the injection, their concentration in the tissues is reduced. Moreover, no change was observed in the cytokine and enzyme levels measured in blood samples; which means there was no considerable inflammatory response or tissue toxicity [11].

Chen et al. studied the acute toxicity of titanium nanoparticles in vivo in mature rats and the effects of nanoparticles were tested on the hepatic parameters, and liver, kidney, and lung tissues at different times (24 and 48 hours; 7 and 14 days). The results showed elevated levels of liver markers Alkalynphosphatase (ALP), glutamate oxaloacetate transaminase (SGOT) and glutamate pyruvate transaminase (SGPT). Furthermore, accumulation of the nanoparticle in the liver, kidney, and lung tissues has been observed. Hepatic necrosis, apoptosis, hepatic fibrosis, renal glomerular inflammation, pneumonia, and pulmonary thrombosis were other conclusions and observations of this study [12].

The difference in tissue distribution, penetration, and damage of nanoparticles in various studies is probably due to the difference in their synthesis method that leads

to changes in size, shape, and other physical and chemical properties of nanoparticles. Therefore, the impact and interaction of nanoparticles with cells and tissues of animals will be different [13].

Because of the very characteristics of TiO₂, a risk assessment of potential adverse effects of nanoparticles on human health and environmental pollution is necessary. Accordingly, in the present study, impact of intraperitoneal injection with different doses of spherical-shape TiO₂ nanoparticles with a diameter of 10 - 15 nm, and inorganic nature, and wet synthesis in the liquid phase, on the function of liver, lung, kidney, and liver enzymes was studied in Wistar male rats.

2. Materials and Methods

2.1. Characterization of TiO₂ Nanoparticles

Two thousand fifty mL TiO₂ was purchased from Tehran Neutrino Co. (Iran) that imports nanoparticles from Spain. In order to make sure of the size of the nanoparticles, 1 g of them was sent to the department of Materials Engineering of the Islamic Azad University (Najafabad branch), and that center confirmed the validity of the nanoparticles size using X-ray tests.

The used TiO₂ nanoparticles were dissolved with the following specifications: density of 3.84 g/mL, specific surface area (SSA) of 100 - 150 m²/g, diameter of 10 - 15 nm, 21.2% rutile and 78.8% anatase, purity of 99.9% and serum concentration of 1000 ppm.

2.2. Mother Solution Preparation

Mother solution was prepared through the following procedure for TiO₂ nanoparticles:

A) 1 mL TiO₂ nanoparticle with a concentration of 1000 ppm + 10 mL double distilled sterile water by Merck, Germany = 10 ppm concentration of titanium dioxide nanoparticles.

B) 10 mL TiO₂ nanoparticles with a concentration of 1000 ppm + 100 mL double distilled sterile water by Merck, Germany = 100 ppm concentration of titanium dioxide nanoparticles.

C) 30 mL TiO₂ nanoparticle with a concentration of 1000 ppm + 300 mL double distilled sterile water by Merck, Germany = 300 ppm concentration of titanium dioxide nanoparticles.

2.3. Animals, Treatment, and Blood Biomarker Assay

In an experimental study, 32 male Wistar rats (mean weight: 225 ± 25 g) were purchased from the Animal Center of Shahrekord university and housed in stainless steel cages in a ventilated animal room. Room temperature was maintained at 20 ± 2°C, with relative humidity of 60 ± 10%, and a 12 hour light/dark cycle.

Distilled water and sterilized food for rats were available ad libitum. They were acclimated to this environment for

7 days prior to dosing. After two weeks of accommodation, rats were randomly divided into 4 groups: control (treated with 0.5 mL normal saline) and 3 experimental groups. Group 1, 2, and 3 received 0.5 mL of solution containing 10, 100, and 300 ppm TiO₂ via intraperitoneal (i.p.) injection for 7 successive days, respectively.

The effects of TiO₂ nanoparticles on serum levels of glutamate oxaloacetate transaminase (SGOT) and glutamate pyruvate transaminase (SGPT) were evaluated at 2nd, 7th and 14th days after the treatment. All animals (at 14th day) were anesthetized by ether and sacrificed for histological assessment.

All animal handling and manipulation procedures were performed according to the guideline of the animal welfare act and the experimental protocols were approved by the office of research ethics committee of university of Shahrekord.

2.4. Biochemical Analysis of Liver Function

Serum was collected by centrifuging blood at 2,500 rpm for 10 minutes. Liver function was evaluated based on the serum levels of SGOT and SGPT. All biochemical assays were performed using a clinical automatic chemistry analyzer (Hitachi Automatic Analyzer 902, Roche, Germany) and Pars Azmon kits (Tehran, Iran).

2.5. Histopathological Examination

Histological observations were performed according to the standard laboratory procedures. A small piece of lung or liver fixed in formalin 10% (v/v) was embedded in a paraffin block, sliced into 5 µm thicknesses and then placed onto glass slides. The section was stained with hematoxylin-eosin (HE) and examined by light microscopy.

All data were analyzed by using the statistical package for social sciences (SPSS-19) software and were summarized and expressed as mean and standard error (mean ± SEM). Statistical analysis of data was performed by Multivariate Analyses of Covariance model (MANCOVA), while serum values at 2, 7, and 14 day after intervention using as dependant variables and baseline value of serum was controlled. We compare between groups. We using Wilk's lambda or Roy largest Root for totally differences between groups, P Value about each depended variables was reported in last row of tables, the Bonferroni posttest was used to paired comparisons. P value less than 0.05 were considered significant.

3. Results

According to MANCOVA P = 0.023; the mean serum glutamic oxaloacetic transaminase (SGOT) was significantly greater in groups receiving TiO₂ (10 ppm and 300 ppm) than the control group 2 days after the intervention; P = 0.002 and P = 0.009, respectively. Seven and 14 days after the injection of TiO₂ 10 ppm and TiO₂ 300 ppm the liver damage was returned (Table 1).

According to MANCOVA P = 0.001; intergroup difference was observed in mean serum glutamic pyruvic transami-

nase (SGPT). Bonferroni posttest was showed the mean SGPT 2 days after the intervention was greater in the group receiving 300 ppm TiO₂ than the groups receiving 100 ppm (P = 0.027) and 10 ppm TiO₂ (P < 0.001) (Table 2).

3.1. Liver Histopathological Evaluation

The histological photomicrographs of the liver sections are shown in Figures 1 - 3.

A: Experimental group 1 (10 ppm TiO₂): hepatocyte vasculature-hypertrophy, approximate elimination of hepatic lobules, and weak acidophilic hepatocyte indicate the impact of the mentioned nanoparticles and prevalence of histopathological changes (Figure 1).

B: Experimental group 2 (100 ppm TiO₂): decreased effect of hepatocyte acidophilic, elimination of hepatic lobules, and central venous hyperemia were considerable histopathological changes in this group (Figure 2).

C: Experimental group 3 (300 ppm TiO₂): significant shrinkage of central veins, immediate hyperemia, elimination of hepatic lobules, hepatocyte hypertrophy, si-

nusoidal thinning, and decreased effect of hepatocyte acidophilic were seen in this group. Besides, a reduction was observed in the size of hepatic artery and portal vein in the portal triad (Figure 3).

3.2. Lung Histopathological Evaluation

Photomicrographs of the lung sections are shown in Figures 4 - 6.

A: Experimental group 1 (10 ppm TiO₂): according to Figure 4, destruction and overlapping of alveolus indicates atelectasis. Moreover, alveolar wall thickening and vasculature hyperemia were seen in this treatment group (Figure 4).

B: Experimental group 2 (100 ppm TiO₂): according to Figure 5, destruction of alveolus, eliminating alveolus, and vasculature hyperemia are evident (Figure 5).

C: Experimental group 3 (300 ppm TiO₂): according to Figure 6, increased thickness of alveolus walls and connective fibrous space are the most considerable changes in this group (Figure 6).

Table 1. Comparison of the Levels of Serum Glutamate Oxaloacetate Transaminase (SGOT) in Studied Groups

Groups	SGOT		
	After 2 Days	After 7 Days	After 14 Days
TiO ₂ 10 ppm	289.3 ± 7.0	279.5 ± 12.8	201.6 ± 9.0
TiO ₂ 100 ppm	275.4 ± 7.8	268.3 ± 11.8	204.6 ± 6.4
TiO ₂ 300 ppm	312.5 ± 15.5	249.3 ± 13.6	194.9 ± 15.4
control	220.4 ± 13.4	253.3 ± 9.4	213.5 ± 15.4
P Value	0.001	0.294	0.886

Table 2. Comparison of the Levels of Serum Glutamate Pyruvate Transaminase (SGPT) in Studied Groups

Groups	SGPT		
	After 2 Days	After 7 Days	After 14 Days
TiO ₂ 10 ppm	129.3 ± 5.2	158.9 ± 12.2	146.0 ± 6.3
TiO ₂ 100 ppm	116.8 ± 7.1	156.4 ± 12.9	154.8 ± 7.9
TiO ₂ 300 ppm	171.3 ± 7.1	165.1 ± 13.9	166.6 ± 12.6
Control	158.3 ± 10.4	170.6 ± 12.0	174.0 ± 13.6
P Value	< 0.0001	0.811	0.309




Figure 1. Light Micrographs of Sections in the Liver of TiO₂-Treated Rat Received 10 ppm, Every Day for 7 Successive Days (Group 1) Demonstrating of Changes Histopathology




Figure 2. Light Micrographs of Sections in the Liver of TiO₂-Treated Rat Received 100 ppm Every Day for 7 Successive Days (Group 2) Demonstrating of Changes Histopathology




Figure 3. Light Micrographs of Sections in the Liver of TiO₂-Treated Rat Received 300 ppm Every Day for 7 Successive Days (Group 3) Demonstrating of Changes Histopathology




Figure 6. Light Micrographs of Sections in the Lung of TiO₂-Treated Rat Received 300 ppm Every Day for 7 Successive Days (Group 3) Demonstrating of Changes Histopathology




Figure 4. Light Micrographs of Sections in the Lung of TiO₂-Treated Rat Received 10 ppm Every Day for 7 Successive Days (Group 1) Demonstrating of Changes Histopathology.




Figure 5. Light Micrographs of Sections in the Lung of TiO₂-Treated Rat Received 100 ppm Every Day for 7 Successive Days (Group 2) Demonstrating of Changes Histopathology.

4. Discussion

The results of this study showed that mean liver enzyme SGOT was significantly greater in groups that received 10 ppm and 300 ppm TiO₂ than the control group two days after the intervention. Seven and 14 days after the injection, the liver damage returned in both groups. Maybe, the other liver enzyme (such as metallothioneine) activated and neutralized the effects of TiO₂ after 7 days. In addition, mean SGPT, two days after the intervention, in the group that received 300 ppm TiO₂ was significantly greater than the groups that received 100 ppm TiO₂ and 10 ppm TiO₂. Higher concentrations of titanium dioxide (300 ppm TiO₂) had a higher toxicity on hepatic enzymes than other concentrations. No difference was observed between the experimental and control groups in terms of mean SGPT. Furthermore, the histological results of liver in group 1 showed hepatocyte vasculature, hypertrophy approximate, in group 2: decreased effect of hepatocyte acidophilic, elimination of hepatic lobules, in group 3: significant shrinkage of central veins, immediate hyperemia showed and histological results in lung: destruction of alveolus and their overlapping (group 1) and vasculature hyperemia in all groups showed. The results indicated intense histopathological changes in lung and liver tissues by 10 - 15 nanometer spherical-shaped TiO₂ nanoparticles in all three experimental groups.

Special features of nanoparticles, such as their small size, shape, high surface area, and their specific construction, are the reasons for the biomedical and industrial applications of these particles [14, 15]. However, in recent years, evidence of the adverse impact of nanoparticles has been reported, such as increased mortality, cardio-respiratory diseases, and malignant asthma [16].

Researchers showed that TiO₂ nanoparticles can damage DNA and cause cell death by induced oxidative stress. In addition, these nanoparticles can produce reactive

oxygen species (ROS) and reduce cell antioxidants such as glutathione and vitamin E [17]. ROS is the physiological products generated during aerobic metabolism in mammalian mitochondria. The intracellular ROS level is balanced through balancing the metabolism (by antioxidant enzymes and scavengers). A number of possible signaling pathways can describe the ROS association with apoptosis including death pathways involving cell-surface receptors (external) and mitochondrial pathways (internal) [18].

Ma et al. reviewed the acute liver damage in mice caused by anatase TiO₂ nanoparticles. In this study, nano-anatase TiO₂ (5 nm) were injected into the abdominal cavity of ICR mice for 14 days and the inflammatory responses in the mice's liver was examined. Results of this study demonstrated the concentration of titanium observable in the liver DNA, histopathological changes, apoptosis in liver hepatocytes, and liver dysfunction with higher doses of nano-anatase TiO₂ [19].

Afaq et al. investigated the titanium dioxide nanoparticle toxicity in rats induced by intratracheal instillation. The peroxidation of lipid and hydrogen peroxide radicals did not change with an increase in the activity of glutathione peroxidase, glutathione reductase, 6-phosphate dehydrogenase, and glutathione S-transferase. This indicates the induction of antioxidant enzymes in animals by nano-TiO₂ (30 nm) [20].

Ma et al. showed that high doses of nano-anatase TiO₂ (5 nm) can cause liver dysfunction, and induced invasion and oxidative stress in rat's liver [21].

Although it is clear that TiO₂ nanoparticles or other nanoparticles can induce serious toxicity in the liver, the molecular mechanisms and pathogenesis have not been identified yet. When TiO₂ nanoparticles stimulate hepatocyte, they are able to induce inhibitory proteins such as phosphorylated I_κBs (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor) and analyze it, and then inhibit NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) activity that ultimately leads to the transcription of proinflammatory and inflammatory cytokine genes in rat's liver [22].

Liu et al. investigated the biochemical toxicity of nano-anatase TiO₂ in mice. In order to evaluate the toxicity of these nanoparticles, they were injected into the abdominal cavity of ICR (imprinting control region) mice for 14 days and the coefficient of the organs and serum biochemical parameters were examined. The results showed that increased dose of these nanoparticles gradually increased the coefficients of liver, kidney, and spleen. Moreover, it gradually decreased the lung and brain coefficients, and the change in brain coefficients was not significant. The order of titanium concentration in organs included: heart < brain < lung < spleen < kidney. Reviewing serum biochemical parameters with a low dose of titanium dioxide nanoparticles, showed a small difference with the control group. However, a high dose of such nanoparticles significantly increased indicators of liver function, including alkaline phosphatase, alanine,

leucine acid peptide, pseudocholinesterase, and total protein and albumin. Renal function indicators, including blood urea nitrogen and uric acid decreased. Indicators of heart function such as activity of aspartate aminotransferase, creatine kinase, dehydrogenase lactate, and alpha-hydroxy butyrate dehydrogenase increased [23].

Olmedo et al. reported that six months after intraperitoneal injection of TiO₂ nanoparticles, the deposition of the nanoparticles in organs such as liver, spleen, and lungs was observed [24]. Results of the study by Huggins and Froehlich showed that after the intravenous injection of 250 mg/kg TiO₂ (size 0.2 - 0.4 nm) in rats, almost 69% of the injected nanoparticles of titanium dioxide at 5 minutes and 80% of injected TiO₂ nanoparticles at 15 minutes were accumulate in the liver. The results indicated that liver deposition was the highest amount among the other tissues [25].

Wang et al. fed TiO₂ nanoparticles to mature rats and evaluated them after two weeks. They observed that 25 and 80 nm nanoparticles in 5 g/kg dose had caused a toxic effect on them and influence biochemical parameters such as ALT, AST, ALP, and Liver pathology. They also did this through intravenous and intraperitoneal injection. Due to the agglomeration of the nanoparticles in liver and kidney cells, liver damage, renal pathological changes and renal inflammation were observed as glomeruli and nephron-like toxic damage to the liver hepatocytes around the central vein lobules. Accumulation of these substances caused abnormal pathological changes in the tissues of the heart, lung, testis, ovary, and spleen [26].

Alkaline phosphatase exists (is distributed) in the liver, bone, bile duct, and ALT and AST in the liver, heart, and other organs. When organs are damaged, the activity of ALP, ALT, and AST increases. It has been indicated that LDH is an important isozyme in glycolysis and glycogen which are present in many tissues and the heart and liver. When tissues are damaged, LDH is released into the blood serum from the organs or cells, leading to an increase in LDH activity and isozymes in similar organs. Pseudocholinesterase (PChE, acylcholine acyl hydrolase), which is found in many animal tissues, acts with low-density in the metabolism of lipids and lipoprotein. When the liver is damaged, PChE activity is dramatically increased which causes impaired lipid metabolism and low-density lipoprotein [27].

In order to find out that apoptotic hepatocyte is induced through the use of intragastric TiO₂ NPs (nanoparticles) for 60 consecutive days, apoptosis of hepatocytes, oxidative stress parameters, and the amount of expression of genes associated with stress in the liver of mice were examined by Cui et al. Results showed that hepatocyte apoptosis, oxidative stress, and altered expression of genes are associated with regulated metabolism/detoxification of titanium dioxide nanoparticles and radical scavenging activities [27].

In this study, the toxic effect of spherical-shaped TiO₂ nanoparticles with a diameter of 10 - 15 nm was evaluated on the function of liver and lung and SGPT and SGOT liver enzymes levels. We faced with increased concentration of

such enzymes in high doses of nanoparticles. Due to damaged liver cells, such enzymes (which are inside the hepatocyte cell) are released into the blood. Therefore, a high amount of such enzymes indicates destruction of liver cells.

Various reports indicated that significant amounts of nanoparticles injected to the body are absorbed by the liver. The reticuloendothelial system in liver can gradually remove the accumulated nanoparticles from the body [28].

Understanding the specific mechanisms of nanoparticles and their reaction requires very extensive research in this area. When nanoparticles are accumulated in a tissue, they may either be absorbed into the cell or no absorption may occur. If these nanoparticles are absorbed, the final cellular replacement in the lysosomal and cytoplasm of the cell will depend on the characteristics of the nanoparticle. If nanoparticles are located in the cytoplasm, some large size material can cause direct damage or cell death by such interactions [29].

It seems that the main mechanism of toxicity is through oxidative stress causes damage to the lipids, carbohydrates, protein, and DNA. Probably the pathological changes in liver tissue are caused by accumulation and deposition of nanoparticles in this tissue [30].

On the other hand, the entry of TiO₂ nanoparticles in this study shows their passing through blood and air barrier and damaging the lung tissue. Among the applications of nanoparticles that help in biological and medical fields is the influence and accumulation of effective nanoparticles in cells and various body organs after its injection [31]. Given the current findings, it can be concluded that application of 10 - 15 nanometer spherical-shaped TiO₂ nanoparticles in vivo, even in small amounts for medical purposes, causes cell toxicity. Further researches are needed to study its effects on organs and blood factors.

Acknowledgements

The authors gratefully acknowledge research funding from Izeh university (Grant number 12464).

Authors' Contributions

Mahbubeh Setorki have analyzed data, interpreted and written the final draft of this manuscript. The animal model used in this study was obtained from the animal Center of Shahrekord university. Monir Doudi has conceived the study and its design.

Financial Disclosure

The authors declare no conflict of interest.

Funding/Support

Islamic Azad University, Izeh and Flavarjan Branches.

References

1. Lai JC, Lai MB, Edgley KL. Silicon dioxide nanoparticles can exert cytotoxic effects on neural cells. *Nanotech*. 2007;2:741-3.

2. Brown JS, Zeman KL, Bennett WD. Ultrafine particle deposition and clearance in the healthy and obstructed lung. *Am J Respir Crit Care Med*. 2002;166(9):1240-7.
3. Kreyling WG, Semmler M, Erbe F, Mayer P, Takenaka S, Schulz H, et al. Translocation of ultrafine insoluble iridium particles from lung epithelium to extrapulmonary organs is size dependent but very low. *J Toxicol Environ Health A*. 2002;65(20):1513-30.
4. Oberdorster G, Sharp Z, Atudorei V, Elder A, Gelein R, Kreyling W, et al. Translocation of inhaled ultrafine particles to the brain. *Inhal Toxicol*. 2004;16(6-7):437-45.
5. Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. *Environ Health Perspect*. 2005;113(7):823-39.
6. Muller J, Huaux F, Moreau N, Misson P, Heilier JF, Delos M, et al. Respiratory toxicity of multi-wall carbon nanotubes. *Toxicol Appl Pharmacol*. 2005;207(3):221-31.
7. Chen HW, Su SF, Chien CT, Lin WH, Yu SL, Chou CC, et al. Titanium dioxide nanoparticles induce emphysema-like lung injury in mice. *FASEB J*. 2006;20(13):2393-5.
8. Tin Tin Win S, Mitsushima D, Yamamoto S, Fukushima A, Funabashi T, Kobayashi T, et al. Changes in neurotransmitter levels and proinflammatory cytokine mRNA expressions in the mice olfactory bulb following nanoparticle exposure. *Toxicol Appl Pharmacol*. 2008;226(2):192-8.
9. Mital GS, Manoj T. A review of TiO₂ nanoparticles. *Chin Sci Bull*. 2011;56(16):1639-57.
10. Ge-yu L, Yue-pu P, Li-hong Y, Ran L, Bing Y, Yao-yao SU, et al. Effects of transbronchial TiO₂ nanoparticles poisoning on liver and kidney in rats. *Teratog Carcinog Mutagen*. 2009;21(2):81-4.
11. Fabian E, Landsiedel R, Ma-Hock L, Wiench K, Wohlleben W, van Ravenzwaay B. Tissue distribution and toxicity of intravenously administered titanium dioxide nanoparticles in rats. *Arch Toxicol*. 2008;82(3):151-7.
12. Chen J, Dong X, Zhao J, Tang G. In vivo acute toxicity of titanium dioxide nanoparticles to mice after intraperitoneal injection. *J Appl Toxicol*. 2009;29(4):330-7.
13. Chaves SB, Lacava LM, Lacava ZGM, Silva O, Pelegrini F, Buske N, et al. Light microscopy and magnetic resonance characterization of a DMSA-coated magnetic fluid in mice. *IEEE Trans Magn*. 2002;38(5):3231-3.
14. Anselmann R. Nanoparticles and nanolayers in commercial applications. *J Nanopart Res*. 2001;3(4):329-36.
15. Grassian VH, O'Shaughnessy P T, Adamcakova-Dodd A, Pettibone JM, Thorne PS. Inhalation exposure study of titanium dioxide nanoparticles with a primary particle size of 2 to 5 nm. *Environ Health Perspect*. 2007;115(3):397-402.
16. Soto K, Garza KM, Murr LE. Biological effects of nanoparticulate materials. *Mater Sci Eng C*. 2006;26(8):1421-7.
17. Johnston HJ, Hutchison GR, Christensen FM, Peters S, Hankin S, Stone V. Identification of the mechanisms that drive the toxicity of TiO₂ particulates: the contribution of physicochemical characteristics. *Part Fibre Toxicol*. 2009;6:33.
18. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. *Cancer Biol Ther*. 2005;4(2):139-63.
19. Ma L, Zhao J, Wang J, Liu J, Duan Y, Liu H, et al. The Acute Liver Injury in Mice Caused by Nano-Anatase TiO₂. *Nanoscale Res Lett*. 2009;4(11):1275-85.
20. Afaq F, Abidi P, Matin R, Rahman Q. Cytotoxicity, pro-oxidant effects and antioxidant depletion in rat lung alveolar macrophages exposed to ultrafine titanium dioxide. *J Appl Toxicol*. 1998;18(5):307-12.
21. Ma L, Liu J, Li N, Wang J, Duan Y, Yan J, et al. Oxidative stress in the brain of mice caused by translocated nanoparticulate TiO₂ delivered to the abdominal cavity. *Biomaterials*. 2010;31(1):99-105.
22. Zhu RR, Wang SL, Chao J. Bio-effects of nano-TiO₂ on DNA and cellular ultrastructure with different polymorph and size. *Mater Sci Eng C*. 2009;29(2):691-6.
23. Liu H, Ma L, Zhao J, Liu J, Yan J, Ruan J, et al. Biochemical toxicity of nano-anatase TiO₂ particles in mice. *Biol Trace Elem Res*. 2009;129(1-3):170-80.
24. Olmedo D, Guglielmotti MB, Cabrini RL. An experimental study of the dissemination of Titanium and Zirconium in the body. *J Mater Sci Mater Med*. 2002;13(8):793-6.

25. Huggins CB, Froehlich JP. High concentration of injected titanium dioxide in abdominal lymph nodes. *J Exp Med*. 1966;**124**(6):1099-106.
26. Wang J, Zhou G, Chen C, Yu H, Wang T, Ma Y, et al. Acute toxicity and biodistribution of different sized titanium dioxide particles in mice after oral administration. *Toxicol Lett*. 2007;**168**(2):176-85.
27. Cui Y, Gong X, Duan Y, Li N, Hu R, Liu H, et al. Hepatocyte apoptosis and its molecular mechanisms in mice caused by titanium dioxide nanoparticles. *J Hazard Mater*. 2010;**183**(1-3):874-80.
28. Wang B, Feng WY, Wang TC, Jia G, Wang M, Shi JW, et al. Acute toxicity of nano- and micro-scale zinc powder in healthy adult mice. *Toxicol Lett*. 2006;**161**(2):115-23.
29. Chaves SB, Silva LP, Lacava ZGM. Interleukine-1 and interleukine-6 production in mice's lungs induced by 2, 3 meso dimercaptosuccinic coated magnetic nanoparticles. *J Appl Phys*. 2005;**1**(97):51-9.
30. Chen Z, Meng H, Xing G, Chen C, Zhao Y, Jia G, et al. Acute toxicological effects of copper nanoparticles in vivo. *Toxicol Lett*. 2006;**163**(2):109-20.
31. Dambach DM, Andrews BA, Moulin F. New technologies and screening strategies for hepatotoxicity: use of in vitro models. *Toxicol Pathol*. 2005;**33**(1):17-26.